The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite- suppressant drugs

New England Journal of Medicine

Volumn 339, Issue 11, 1998, Pages 713-718

  Khan, Mehmood A ^a,e,f   Herzog, Charles A ^a   St Peter, John V ^a,e   Hartley, Guilford G ^a,e   Madlon Kay, Richard ^b   Dick, Candace D ^c   Asinger, Richard W ^a   Vessey, John T ^d,e  

^a HealthSystem Minnesota   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c Minnesota Heart Clinic   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e University of Minnesota   (United States)

^f Division of Endocrinology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; BODY MASS; DATA ANALYSIS; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; OBESITY; PREVALENCE; PRIORITY JOURNAL; REPRODUCIBILITY; RISK ASSESSMENT; TRANSTHORACIC ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE;

ADULT; AORTIC VALVE INSUFFICIENCY; APPETITE DEPRESSANTS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DRUG COMBINATIONS; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FENFLURAMINE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; OBESITY; OBSERVER VARIATION; PHENTERMINE; PREVALENCE;

EID: 0032504948     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199809103391101     Document Type: Article

References (31)

1. Weintraub M, Sundaresan PR, Madan M, et al. Long-term weight control study. I. (Weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992;51:586-94.
2. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study. II. (Weeks 34 to 104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther 1992;51:595-601.
3. Weintraub M, Sundaresan PR, Schuster B, Moscucci M, Stein EC. Long-term weight control study. III. (Weeks 104 to 156): an open-label study of dose adjustment of fenfluramine and phentermine. Clin Pharmacol Ther 1992;51:602-7.
4. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study. IV. (Weeks 156 to 190): the second double-blind phase. Clin Pharmacol Ther 1992;51:608-14.
5. Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Byrne L. Long-term weight control study. V. (Weeks 190 to 210): follow-up of participants after cessation of medication. Clin Pharmacol Ther 1992;51:615-8.
6. Weintraub M, Sundaresan PR, Cox C. Long-term weight control study. VI. Individual participant response patterns. Clin Pharmacol Ther 1992;51: 619-33.
7. Weintraub M, Sundaresan PR, Schuster B. Long-term weight control study. VII. (Weeks 0 to 210): serum lipid changes. Clin Pharmacol Ther 1992;51:634-41.
8. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther 1992;51:642-6.
9. Idem. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992;51:581-5. [Erratum, Clin Pharmacol Ther 1992;52:323.]
10. Kushner R. The treatment of obesity: a call for prudence and professionalism. Arch Intern Med 1997;157:602-4.
11. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061-6.
12. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8. [Erratum, N Engl J Med 1997;337:1783.]
13. Hartley GG, Nicol S, Halstenson C, Khan M, Pheley A, St Peter JV. Long-term results from phentermine, fenfluramine, diet, behavior modification, and exercise for treatment of obesity. Obes Res 1997;5 Suppl 1:58S. abstract.
14. Khan MA, St Peter JV, Hartley GG, Pheley AM, McFarland KA. The effect of adding phentermine to weight management therapy in patients with declining response to dexfentluramine alone. Obes Res 1997;5:Suppl 1:22S. abstract.
15. Perry GJ, Helmcke F, Nanda NC, Byard C, Soto B. Evaluation of aortic insufficiency by Doppler color flow mapping. J Am Coll Cardiol 1987; 9:952-9.
16. Dolan MS, Castello R, St Aguirre F, Labovitz AJ. Quantitation of aortic regurgitation by Doppler echocardiography: a practical approach. Am Heart J 1995;129:1014-20.
17. Tribouilloy C, Shen WF, Slama M, et al. Assessment of severity of aortic regurgitation by M-mode colour Doppler flow imaging. Eur Heart J 1991;12:352-6.
18. Bargiggia GS, Tronconi L, Sahn DJ, et al. A new method for quantitation of mitral regurgitation based on color flow Doppler imaging of flow convergence proximal to regurgitant orifice. Circulation 1991;84:1481-9.
19. Enriquez-Sarano M, Seward JB, Bailey KR, Tajik AJ. Effective regurgitant orifice area: a noninvasive Doppler development of an old hemodynamic concept. J Am Coll Cardiol 1994;23:443-51.
20. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984;70:657-62.
21. Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985;6:359-65.
22. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1985;6:750-6.
23. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients. Circulation 1993; 87:1188-96.
24. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790-5.
25. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50-2.
26. Akasaka T, Yoshikawa J, Yoshida K, et al. Age-related valvular regurgitation: a study by pulsed Doppler echocardiography. Circulation 1987;76: 262-5.
27. Yoshida K, Yoshikawa J, Shakudo M, et al. Color Doppler evaluation of valvular regurgitation in normal subjects. Circulation 1988;78:840-7.
28. Choong CY, Abascal VM, Weyman J, et al. Prevalence of valvular regurgitation by Doppler echocardiography in patients with structurally normal hearts by two-dimensional echocardiography. Am Heart J 1989;117:636-42.
29. Klein AL, Burstow DJ, Tajik AJ, et al. Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiogr 1990;3:54-63.
30. Reid CL, Gardin JM, Yunis C, Kurosaki T, Flack JM. Prevalence and clinical correlates of aortic and mitral regurgitation in a young adult population: the CARDIA Study. Circulation 1994;90:Suppl I:I-282. abstract.
31. Gray GW, Salisbury DA, Gulino AM. Echocardiographic and color flow Doppler findings in military pilot applicants. Aviat Space Environ Med 1995;66:32-4.